Publications by authors named "Raymond Alexanian"

Claim this Profile
S
Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up.
Elisabet E Manasanch, Chutima Kunacheewa, Catherine M Claussen, Hans C Lee, Sheeba K Thomas, Raymond Alexanian

Blood Cancer J· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Hans C Lee, Jatin J Shah, Lei Feng, Ashley Morphey, Ralph J Johnson, Raymond Alexanian

Am J Hematol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Hans C Lee, Jatin J Shah, Lei Feng, Elisabet E Manasanch, Rebecca Lu, Raymond Alexanian

Blood Cancer J· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
Samer Tabchi, Rajit Nair, Chutima Kunacheewa, Krina K Patel, Hans C Lee, Raymond Alexanian

Clin Lymphoma Myeloma Leuk· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chondromyxoid fibroma involving the sphenoid sinus: Case report and literature review.
Tamara Miner Haygood, Mark Herndon, Pranav Chitkara, Raymond Alexanian

Radiol Case Rep· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study.
M Kay Garcia, Lorenzo Cohen, Ying Guo, Yuhong Zhou, Bing You, Raymond Alexanian

J Hematol Oncol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High frequencies of response after limited primary therapy for multiple myeloma.
Raymond Alexanian, Kay Delasalle, Michael Wang

Clin Lymphoma Myeloma Leuk· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma.
Weijun Fu, Kay Delasalle, Jialei Wang, Shen Song, Jian Hou, Raymond Alexanian

Am J Clin Oncol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study.
Haijun Wang, Yiming Chen, Fanglin Li, Kay Delasalle, Jialei Wang, Raymond Alexanian

Cancer· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Curability of multiple myeloma.
Raymond Alexanian, Kay Delasalle, Michael Wang, Sheeba Thomas, Donna Weber

Bone Marrow Res· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy.
Valerie Reed, Jatin Shah, L Jeffery Medeiros, Chul S Ha, Ali Mazloom, Raymond Alexanian

Cancer· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
Sundar Jagannath, Bart Barlogie, James R Berenson, David S Siegel, David Irwin, Raymond Alexanian

Br J Haematol· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
Anna V Christoforidou, Rima M Saliba, Patricia Williams, Muzaffar Qazilbash, Linda Roden, Raymond Alexanian

Biol Blood Marrow Transplant· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current treatment strategies for multiple myeloma.
Sheeba Thomas, Raymond Alexanian

Clin Lymphoma Myeloma· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Paul G Richardson, Hannah Briemberg, Sundar Jagannath, Patrick Y Wen, Bart Barlogie, Raymond Alexanian

J Clin Oncol· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
James R Berenson, Sundar Jagannath, Bart Barlogie, David T Siegel, Raymond Alexanian

Cancer· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma.
Michael Wang, Donna M Weber, Kay Delasalle, Raymond Alexanian

Am J Hematol· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Sundar Jagannath, Bart Barlogie, James R Berenson, Seema Singhal, Raymond Alexanian

Cancer· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How we treat Waldenström's macroglobulinemia.
Meletios A Dimopoulos, Giampaolo Merlini, Veronique Leblond, Athanasios Anagnostopoulos, Raymond Alexanian

Haematologica· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression.
Meletios A Dimopoulos, Raymond Alexanian, Dimitra Gika, Athanasios Anagnostopoulos, Constantinos Zervas

Leuk Lymphoma· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
Athanasios Anagnostopoulos, Ana Aleman, Gregory Ayers, Michele Donato, Richard Champlin, Raymond Alexanian

Cancer· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis.
Alok C Bharti, Shishir Shishodia, James M Reuben, Donna Weber, Raymond Alexanian

Blood· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma.
Michele L Donato, Ana Aleman, Richard E Champlin, Donna Weber, Raymond Alexanian

Leuk Lymphoma· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma.
Raymond Alexanian, Donna Weber, Athanasios Anagnostopoulos, Kay Delasalle, Michael Wang

Semin Hematol· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Paul G Richardson, Bart Barlogie, James Berenson, Seema Singhal, Sundar Jagannath, Raymond Alexanian

N Engl J Med· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis